martes, 1 de octubre de 2024

FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia - Cobenfy (xanomeline and trospium chloride) capsules for oral use

https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia

No hay comentarios:

Publicar un comentario